Somatostatin-like Immunoreactivity Research Articles

Working memory deficits following muscarinic blockade combined with depletion of brain somatostatin in rats

In a working memory task with three-panel runway paradigm, cysteamine, a depletor of somatostatin, at 100 or 200 mg/kg i.p. given 24 h before testing, had no effect on the number of errors (attempts to pass through two incorrect panels of the three panel-gates at four choice points). Cysteamine at 100 mg/kg caused a significant reduction in somatostatin-like immunoreactivity in the rat brain, including the hippocampus and cerebral cortex. Working memory errors were significantly increased by scopolamine, a muscarinic receptor antagonist, at 0.32 mg/kg i.p. given 20 min before testing, whereas errors were not affected by the 0.1 mg/kg dose. Combined administration of 100 mg/kg cysteamine and 0.1 mg/kg scopolamine significantly increased the number of working memory errors. However, cysteamine at 100 mg/kg and scopolamine at 0.1 mg/kg had no effect on reference memory errors, whether they were administered alone or in combination. These results suggest that depletion of brain somatostatin aggravates working memory deficits induced by blockade of muscarinic receptors.

ACTIVATION OF NICOTINIC CHOLINERGIC RECEPTORS MODULATES THE SOMATOSTATINERGIC SYSTEM IN THE RAT HYPOTHALAMUS

Acetylcholine potentiates the excitatory effect of somatostatin (SS) on brain neurons and nicotine, a cholinergic drug, modifies catecholamine turnover in the hypothalamus. The hypothalamus shows a high concentration of nicotinic cholinergic receptors and a dense innervation of SS-positive nerve terminals. In light of these findings, we studied the effect of intravenous (i.v.) nicotine injection (0.3 mg/kg) on SS peptide levels and receptor binding in the hypothalamus of male Sprague-Dawley rats. A second experimental group was pretreated with mecamylamine (5 mg/kg), a centrally acting antagonist of nicotinic cholinergic receptors, in order to evaluate whether the effects of nicotine on the studied system involved the activation of these receptors. Control rats received an i.v. saline injection. The rats were killed 4 min after i.v. administration, and the hypothalamus was dissected to isolate SS and its membrane receptors.Results: Nicotine produced an increase in somatostatin-like immunoreactivity (SLI) and in SS receptors. When the rats were pretreated with mecamylamine, the effects of nicotine were inhibited. Mecamylamine alone did not influence either parameter.Conclusions: 1. These results suggest that the rat hypothalamic somatostatinergic system is regulated by nicotine-like acetylcholine receptors. 2. The somatostatinergic system may be involved in some of the neuroendocrine effects of nicotine.

The effect of diazepam and the benzodiazepine antagonist CGS 8216 on the somatostatinergic neuronal system

The effects of the benzodiazepines and somatostatin (SS) on learning and memory are the opposite of each other. To investigate a possible relationship between these two components, the effects of the administration over time of diazepam and of a benzodiazepine antagonist, 2-phenylpyrazolo [3,4-c]-quinolin-3(5H)-one (CGS 8216), on the levels of somatostatin-like immunoreactivity (SSLI) and on the binding of [ 125I]Tyr 11-somatostatin were studied in the hippocampus of the Wistar rat. Diazepam (5 mg/kg/day, i.p.) and CGS 8216 (20 mg/kg/day, i.p.) did not affect SSLI in the hippocampus, at the three times studied (3, 7 or 14 days). Administration of diazepam for 3 or 7 days decreased the number of somatostatin receptors in synaptosomes from the hippocampus, without influencing their apparent affinity. This decrease could be blocked by concomitant administration of CGS 8216, whereas CGS 8216 alone had no observable effect. After 2 weeks of daily injections of diazepam the levels of binding of somatostatin in the hippocampus returned to control values, coinciding with the tolerance that develops to chronically-administered benzodiazepine agonists. These results suggest that somatostatin receptors might be regulated by benzodiazepine receptors and perhaps may also play a role in some of the behavioural effects of the benzodiazepines.

Somatostatin-like immunoreactivity in the pigeon visual system: developmental expression and effects of retina removal.

The distribution of somatostatin (SS)-containing neurons was investigated by immunocytochemical methods in the central visual system of adult, developing, and retina-ablated pigeons. In normal adult brains, SS-positive cells and processes were present in the optic tectum, the nucleus of the basal optic root, the visual Wulst, and the ectostriatum. During development, progressive increase or decrease in the numerical density and the total number of SS-containing neurons occurred as determined by quantitative analysis. Changes in SS immunoreactivity also occurred as a consequence of unilateral and bilateral retina removal immediately after hatching, i.e. before retinofugal connections have been established. In spite of the segregation of visual inputs due to the almost completely crossed retinal projections, unilateral and bilateral deafferentation differentially affected SS-containing visual regions. In addition, different effects were observed on the relative packing density of labeled cells as compared to their total number. A possible role of retinal axons in regulating the distribution of SS immunoreactivity was suggested by its altered expression induced by retinal deafferentation. In addition, parallels with the distribution of SS immunoreactivity in the pigeon's visual system were used to suggest possible equivalence between cell populations in the avian and the mammalian brains.

Somatostatin-like immunoreactivity is found in dendritic guard cells of human sweat ducts

Somatostatin is reported in a new population of human sweat duct cells. The epithelial content of somatostatin-like immunoreactivity in normal human skin from various sites of the body was investigated using indirect immunofluorescence. With this methodology we found round-to-oval somatostatin-immunoreactive cells situated outside the lining sweat duct cells at the level of the stratum spinosum. The cells had processes that were clearly directed towards the duct lumen, passing between the lining duct cells. This finding raises new questions and ideas about somatostatin's role in the skin, and could point to a possible involvement of somatostatin in immune defense, sweat secretion modification, antiproliferation, or other actions.

Endogenous circadian rhythmicity of somatostatin like-immunoreactivity in the rat suprachiasmatic nucleus

The suprachiasmatic nucleus (SCN) of the hypothalamus has been established as the locus of the circadian pacemaker in mammals. The SCN is histochemically divided into two subdivisions: dorsomedial and ventrolateral subfields. The dorsomedial SCN is characterized, in part, by dense somatostatin-like immunoreactivity (SS-LI), but its functional significance in circadian pacemaking remains unclear. Our previous study revealed that 24 h SS-LI contents of the SCN in rats kept under light-dark (LD) conditions or blinded by orbital enucleation showed a distinct circadian rhythm. In the present study, 24 h SS-LI contents of the SCN in sighted rats kept under constant darkness (DD) conditions for prolonged periods were measured by enzyme immunoassay. Cellular contents of SS-LI exhibited a clear circadian rhythm on the third day of constant darkness (DD) with a peak at circadian time (CT) 5, corresponding to the time of peak levels found in LD conditions and in enucleated animals. This endogenous free-running rhythm continued to oscillate without attenuation of the amplitude even at 14 days in constant darkness. Moreover, SS-LI rhythm was found to be similar to the vasopressin rhythm in the SCN. In summary, these findings further strengthen the idea that the cellular content of SS-LI in the SCN is under the control of the endogenous circadian pacemaker.

Manganese Injection into the Rat Striatum Produces Excitotoxic Lesions by Impairing Energy Metabolism

There is compelling evidence that excessive exposure to manganese (Mn) produces neurotoxicity, especially in the basal ganglia, resulting in a dystonic Parkinsonian disorder. Several experimental or clinical observations suggest that Mn neurotoxicity could involve impairment of energy metabolism. We examined the neurotoxic effects of Mn following local intrastriatal injection. Three hours after the injection of 2 μmol of MnCl 1 into rat striatum, ATP levels were reduced to 51% of the control side and lactate level were increased by 97%, indicating an impairment of oxidative metabolism. Neurochemical analysis of the striata 1 week after Mn injection showed changes consistent with a N-methyl- d-aspartate (NMDA) excitotoxic lesion. Dopamine, γ-aminobutyric acid, and substance P concentrations showed dose-dependent significant decreases, but concentrations of somatostatin-like immunoreactivity and neuropeptide Y-like imunoreactivity were unchanged. The lesions were blocked by prior removal of the cortico-striatal glutamatergic input or by treatment with the noncompetitive NMDA antagonist MK-801. These findings indicate that Mn neurotoxicity involves a NMDA receptor-mediated process similar to that we have previously found with two characterized mitochondrial toxins, aminooxyacetic acid, and 1-methyl-4-phenylpyridinium. Our results show that Mn may produce neuronal degeneration by an indirect excitotoxic process secondary to its ability to impair oxidative energy metabolism.

Role of somatostatin in glucose regulation during endotoxicosis in the rat.

This study assessed the role of somatostatin in regulating glucose homeostasis during endotoxicosis in the rat. Plasma levels of somatostatin, glucose, lactate, insulin, and glucagon were measured in control and endotoxin-treated rats. Cysteamine was used to block endogenous somatostatin release before endotoxin treatment. Early during the course of endotoxicosis, plasma levels of somatostatin-like immunoreactivity (SLI) were significantly elevated along with glucose, lactate, insulin, and glucagon. Pretreatment of endotoxic rats with cysteamine virtually blocked the elevated SLI levels and prevented the early appearance of hyperglycemia. Endotoxin-induced increases in lactic acid and glucagon levels were attenuated by cysteamine pretreatment, but elevated insulin levels were not appreciably altered. Elevated somatostatin levels appeared to support the occurrence of the early hyperglycemia and prevent the development of late hypoglycemia during endotoxicosis by sustaining elevated glucagon levels and thus facilitating the maintenance of glucose levels. The results suggest that somatostatin plays a significant role in the glucoregulatory response to endotoxicosis. Endotoxicosis may alter the relative "physiological" ability of somatostatin to inhibit the secretion of insulin and glucagon.

Extracellular somatostatin measured by microdialysis in the hippocampus of freely moving rats: evidence for neuronal release.

Intracerebral microdialysis combined with a sensitive and specific radioimmunoassay was used to monitor the neuronal release of somatostatin (somatostatin-like immunoreactivity, SLI) in the dorsal hippocampus of freely moving rats. The sensitivity of the radioimmunoassay was optimized to detect < 1 fmol/ml. The basal concentration of SLI in 20-min dialysate fractions (5 microliters/min) collected 24 h after probe implantation was stable over at least 200 min. The spontaneous efflux dropped by 54 +/- 6.4% (p < 0.05) when Ca2+ was omitted and 1 mM EGTA added to the Krebs-Ringer solution and by 65.5 +/- 3.2% (p < 0.05) in the presence of 1 microM tetrodotoxin. Depolarizing concentrations of the Na+ channel opener veratridine (6.25, 25, 100 microM) induced 11 +/- 2 (p < 0.05), 17 +/- 2 (p < 0.05), and 21 +/- 5 (p < 0.01) fold increase in SLI concentration, respectively, during the first 20 min of perfusion. The effect of 100 microM veratridine was blocked by coperfusion with 5 microM tetrodotoxin (p < 0.01) and reduced by 79% (p < 0.01) in the virtual absence of Ca2+. Neuronal depolarization by 20 min of perfusion with Krebs-Ringer solution containing 25 and 50 mM KCl and proportionally lowered Na+ increased the dialysate SLI 4.4 +/- 1 (p < 0.05) and 17 +/- 3 (p < 0.01) fold baseline, respectively. Ten micromolar ouabain, a blocker of Na+,K(+)-ATPase, increased the dialysate SLI 15-fold baseline, on average (p < 0.05), during 80 min of perfusion. The results demonstrate the suitability of brain microdialysis for monitoring the neuronal release of SLI and for studying its role in synaptic transmission.

CSF somatostatin in Alzheimer's disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and clinical measures

Patients with Alzheimer's disease (AD) and major depression have been shown to have overlapping clinical symptoms and biological markers, including decreased concentrations of cerebrospinal fluid (CSF) somatostatin-like immunoreactivity (SLI), which may be related to alterations in the hypothalamic-pituitary-adrenal axis activity. As in prior studies, we found that CSF SLI was significantly decreased in a group of AD patients ( N = 49) and a group of elderly patients with major depression ( N = 18), as compared with 13 age-matched controls ( F[2, 77] = 12.9, p < .001). In the present study, CSF SLI and CSF corticotropin-releasing factor correlated significantly within the group of AD patients ( r = 0.49, p < .0004) and almost attained significance in the depressed patients ( r = 0.47, p < .07). CSF SLI correlated significantly with urinary free cortisol within each patient group ( r = −0.51, p < .03). Clinical measures of dementia severity and depression did not consistently correlate with CSF SLI in either patient group.

Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin.

The extent to which the plasticity in peptide expression observed in developing spinal motoneurons occurs following proximal peripheral axotomy in the adult rat was examined using in situ hybridization and immunohistochemical techniques to visualize the changes. Transient upregulation of galanin, vasoactive intestinal polypeptide (VIP) and substance P messenger ribonucleic acids (mRNAs) was observed within subpopulations of motoneurons ipsilateral to lesion for periods lasting 2-3 weeks after injury. In contrast, the axotomy-induced heterogenous increases in somatostatin and neuropeptide tyrosine mRNA expression in ipsilateral motoneurons remained elevated, or, in the case of somatostatin, continued to increase for the time period studied (1 month). Immunohistochemical analysis agreed with the in situ hybridization results, showing some motoneurons within the injured ventral horn to contain galanin-, VIP- or somatostatin-like immunoreactivity. In some instances, galanin-immunoreactive motoneurons colocalized with calcitonin gene-related peptide immunoreactivity. Most of the neurons expressing the injury-induced peptides appeared large, presumably alpha-motoneurons but there were also many small neurons expressing galanin in the ventral horn ipsilateral to lesion. This may represent evidence for peptide synthesis in gamma-motoneurons. The only peptide mRNA studied to be down-regulated in response to axotomy was enkephalin. The results show that peptide expression in injured motoneurons is dramatically altered, the significance of which remains to be determined.

In vivo release of somatostatin from rat hippocampus and striatum

Rats were implanted with microdialysis probes in hippocampi and striata, and somatostatin-like immunoreactivity (SS-LI) was measured in outflows obtained from awake, freely moving animals 48 and 72 h post implantation. SS-LI was measurable in all dialysates under basal conditions; concentrations were stable and within a narrow range, about 3–6 fmol/ml. Cysteamine (300 mg/kg, s.c.) markedly reduced basal SS-LI concentrations in outflows from hippocampus ( P < 0.00001). KCl (100 mM, 10 min) or veratridine (50 μM, 10 min) infusion elevated hippocampal SS-LI output by 55 and 106%, respectively ( P's < 0.05). EGTA (10 mM) or tetrodotoxin (2 μM) infusion inhibited the SS-LI release elicited by KCl and veratridine, respectively, without affecting the basal SS-LI outflow. Thus, our results demonstrate that SS-LI is released from rat hippocampus and striatum in vivo, and provide evidence that the peptide may be released in hippocampus by both action potential dependent and independent processes.

Effect of prenatal dopamine receptor blocking on somatostatin receptor binding in the developing rat brain

To date, the possible functional interaction between the dopaminergic and the somatostatinergic system during the development of the brain is unknown. This study examines whether blockage of brain dopamine receptors during fetal life might influence postnatal somatostatin (SS) receptor development. Pregnant Sprague-Dawley rats were injected intraperitoneally with either haloperidol (2.5 mg/kg/day), which blocks dopaminergic receptors, or saline. The injections were given for 16 days, commencing on the 4th or 5th day after conception (as counted from the appearance of spermatozoa in daily vaginal smear). The administration of haloperidol during gestation did not affect the levels of somatostatin-like immunoreactivity (SLI) in the two brain areas at any of the times studied. However, this treatment resulted in a decrease in the total number of receptors for 125I-Tyr 11-SS in frontoparietal cortex and hippocampal plasma membranes in the 14-day-old offspring but not at 21, 35, or 60 days after birth. No significant differences in the apparent SS binding affinity values were seen after fetal exposure to haloperidol. These results suggest that the development of SS receptors in rat frontoparietal cortex and hippocampus can be transitorily delayed by fetal blockage of dopamine receptors.

Effect of acute and chronic diisopropylfluorophosphate and atropine administration on somatostatin binding in the rat frontoparietal cortex and hippocampus.

The acute and chronic administration of diisopropylfluorophosphate (DFP), an inhibitor of acetylcholinesterase (AChE), and of atropine, a blocker of muscarinic cholinergic receptors, did not affect somatostatin-like immunoreactivity (SLI) content in the frontoparietal cortex and hippocampus of rats. Acute and chronic DFP administration increased the number of specific 125I-Tyr11-somatostatin (125I-Tyr11-SS) receptors in synaptosomes from the frontoparietal cortex but not in those from the hippocampus and did not change the affinity constant. This increase in 125I-Tyr11-SS binding was not due to a direct effect of DFP on somatostatin (SS) receptors since no rise of binding was produced by high concentrations of DFP (10(-5) M) when added in vitro. The increase could be blocked by pretreatment with atropine. The acute administration of atropine alone had no observable effect on the number of SS receptors. However, repeated atropine administration produced a significant decrease in the 125I-Tyr11-SS binding in synaptosomes from the frontoparietal cortex but not in those from the hippocampus although the affinity constant was unchanged. The results suggest that interactions between somatostatinergic and cholinergic receptors may be important in the rat frontoparietal cortex.

Quantitative Electroencephalographic Correlates of Steroid Administration in Man

Elevated levels of circulating corticosteroids are frequently associated with behavioral alterations in man, although the mechanisms by which corticosteroids may affect behavior are poorly understood. To evaluate possible effects of exogenous corticosteroids on brain electrophysiological functioning and the relationship of such effects to behavioral and biochemical changes, we administered prednisone (80 mg p.o. daily for 5 days) in a double-blind manner to 11 medically healthy volunteers. Quantitative electroencephalogram analysis was performed following 4 days of prednisone administration and during the preceding and ensuing placebo administration periods. Central theta wave brain electrical activity significantly increased following prednisone administration and returned to baseline following prednisone withdrawal. This effect was directly correlated with prednisone-induced increases in subjective sadness ratings and with decreases in self-rated energy and well-being. Prednisone-induced reductions in peak alpha wave activity were also directly correlated with increases in subjective sadness and Symptom Checklist-90 ratings and with decreases in self-rated 'hypomanic' symptoms. Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. This preliminary report of the concomitant development of prednisone-induced changes in brain electrical activity, neurochemistry and behavior highlights areas for future exploration in the study of corticosteroid effects on behavior in man.

Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization

Excitotoxin lesions induced by quinolinic acid (QA) were made unilaterally in the caudate nucleus and putamen of 12 rhesus monkeys. Both acute (2-3 weeks) and chronic (4-6 months) effects were evaluated. Excitotoxin striatal lesions were characterized by a central zone of intense astrogliosis and marked neuronal depletion, which was surrounded by a transition zone in which there was partial neuronal sparing throughout the entire lesioned side. Immunocytochemical and enzyme histochemical markers for both large and medium-sized aspiny- and spiny-striatal neurons clearly demonstrated a selective pattern of neuronal vulnerability to the excitotoxic effects of QA within lesioned striata. Medium-sized spiny neurons containing calbindin Dk28, enkephalin, and substance P were disproportionately lost, while aspiny neuronal subpopulations containing NADPH diaphorase (NADPH-d) and choline acetyltransferase activity (ChAT) were relatively spared. Combined labeling by NADPH-d enzyme histochemistry and Nissl staining, as well as NADPH-d histochemistry and calbindin Dk28 immunocytochemistry, demonstrated significant increases in the ratio of aspiny to spiny neurons within the lesioned striata. Neurochemical measurements confirmed a loss of GABA and substance P-like immunoreactivity yet no significant depletion of somatostatin-like immunoreactivity, neuropeptide Y-like immunoreactivity, or ChAT were seen. The striatal patch-matrix pattern persisted, as demonstrated by acetylcholinesterase activity. The pattern was altered, however, in the chronic animals, such that the matrix zone was significantly reduced, while the total area of patches remained within normal limits. Ultrastructural analysis confirmed axon sparing lesions with neuronal loss and astrogliosis. Pretreatment of 3 monkeys with MK-801, a noncompetitive N-methyl- d-aspartate (NMDA) antagonist, blocked striatal QA neurotoxicity. The present results provide an experimental primate model which closely resembles the neuropathologic and neurochemical features of Huntington's disease. These findings further strengthen the possibility that an NMDA receptor-mediated excitotoxic process plays a role in the pathogenesis of this disorder.

Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment

A radioimmunoassay procedure was used to determine levels of somatostatin-like immunoreactivity in cerebrospinal fluid obtained from 9 schizophrenic patients, 7 patients with other psychiatric disorders, and 10 nonpsychiatric surgical controls. There were no significant differences in mean somatostatin baseline levels between the schizophrenic, and surgical patients. The concentrtion remained almost unaltered after 4 weeks of zuclopenthixol treatment in the schizophrenia group and following various neuroleptic, antidepressant, and anxiolyic medications in the nonschizophrenic patients despite a significant decrease of over psychopathology assessed by the Brief Psychiatric Rating Scale.

Effect of serotonin axon injury on the somatostatinergic system in rat frontoparietal cortex

In order to investigate the possibility that, in the rat, some cerebral cortex somatostatin (SS) receptors may be localized presynaptically on the terminals of serotonergic neurons, serotonin [5-hydroxytryptamine, (5-HT)] neurons in the central nervous system were damaged with a local intracerebral injection of the serotonergic neurotoxin, 5, 7-dihydroxytryptamine (5, 7-DHT). The injection of 5, 7-DHT (11 μg free base dissolved in 10 μl of isotonic saline containing 0.01% ascorbic acid) in rats produced an reduction by about 74% in frontoparietal cortical 5-HT content at 1 and 3 weeks after injection. These changes were associated with a significant decrease by about 30% in the total number of specific SS receptors in the frontoparietal cortex at both times studied without influencing the apparent affinity of the receptors. Together, these results suggest that a portion of the frontoparietal cortex SS receptors may be localized presynaptically on the serotonergic nerve terminals. The 5, 7-DHT did not affect SS-like immunoreactivity (SSLI) levels suggesting that SS and 5-HT are not colocalized within the same neuronal elements in the rat frontoparietal cortex.

Somatostatin release in rat neocortex during gamma-hydroxybutyrate-provoked seizures: Microdialysis combined with EEG recording

Gamma-hydroxybutyrate (GHB) was intracortically applied in two doses (first 10 and then 20 mg/ml) to awake Wistar rats using microdialysis. Simultaneously, EEG and the release of somatostatin-like immunoreactivity (SLI) were measured from the frontal cortex. Intracerebrally administered GHB induced cortical epileptogenic spikes, but not high voltage spindles (HVS) as reported after systemic administration, and seizures with myoclonic jerks and contraversive head movements. Compared to the basal level, GHB (10 mg/ml) initially increased the release of SLI ( p < 0.05). However, when the frequency of spikes and seizures rose rapidly ( p < 0.001), SLI release decreased significantly ( p < 0.001). Minimum release of SLI occured when seizures were most frequent (during perfusion with 20 mg/ml GHB), while after removal of the drug it rose above the basal level ( p < 0.05). According to these results, intracortically applied GHB increases the release of SLI in the surrounding tissue. However, further exposure of GHB leads to a manifestation of epileptic spikes and seizures, during which the release of SLI is significantly attenuated. This suggests that release of Somatostatin is affected during epileptic phenomena induced also by intracortical GHB application.

Effect of serotonergic agents on regional concentrations of somatostatin- and neuropeptide Y-like immunoreactivities in rat brain

A possible role for neuropeptides in affective disorders is suggested by many investigators. Somatostatin-like immunoreactivity (SS-LI) and neuropeptide Y-like immunoreactivity (NPY-LI) concentrations are demonstrated to be reduced in cerebrospinal fluid from depressed patients. We have shown that long-term treatment with serotonin uptake inhibitors, clomipramine and zimelidine, reduce brain SS-LI concentrations in the rat. We have studied the effect of serotonergic agents on regional brain SS-LI and NPY-LI concentrations in rats. Long-term treatment with 5-hydroxytryptamine (5-HTP), a serotonin precursor, caused reductions in SS- and NPY-LI levels in the hypothalamus. SS-and NPY-LI concentrations in the brain were markedly elevated by treatment with p-chlorophenylalanine, a serotonin synthesis inhibitor. Intracerebroventricular administration of 5,7-dihydroxytryptamine, a serotonin neurotoxin, resulted in elevations of both peptides in the brain. These results suggest a inhibitory role for the serotonergic system in the brain in the regulation of SS and NPY.